Solid Tumors Clinical Trials

A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1323 clinical trials
A Study of SGN-B6A in Advanced Solid Tumors

It will also study whether SGN-B6A works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-B6A should be given to participants. Part B will use the dose found in Part A to find out how safe SGN-B6A is …

gastric cancer
ovarian ca
pancreatic adenocarcinoma
bladder cancer
lung cancer
  • 0 views
  • 05 Aug, 2020
A Study of SY 5609 a Selective CDK7 Inhibitor in Advanced Solid Tumors

This is a dose escalation study and will be the first to administer SY-5609 alone to humans with select advanced solid tumors and in combination with Fulvestrant to patients with HR positive, HER2-negative breast cancer.

health screening
alopecia
solid tumor
endocrine therapy
human chorionic gonadotropin
  • 0 views
  • 16 Feb, 2024
  • 5 locations
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of BPI-1178 in subjects with advanced solid tumor, as well as the subjects with advanced hormone receptor-positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer.

human epidermal growth factor
advanced solid tumor
aptt
thromboplastin
immunostimulant
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Phase 1 Multi-Center Safety Dose Escalation Pharmacokinetics of INV-1120 in Adult Patients Advanced Solid Tumors

The safety, tolerability, and PK of INV-1120 will be assessed in adult patients with advanced solid tumors.

computed tomography
beta human chorionic gonadotropin
ct scan
solid neoplasm
renal function
  • 0 views
  • 16 Feb, 2024
  • 2 locations
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Giving avelumab together with M6620 may help to control DDR deficient metastatic or unresectable solid tumors.

BRCA1
FANCD2
metastatic castration-resistant prostate cancer
liver metastases
opportunistic infection
  • 0 views
  • 16 Feb, 2024
  • 1 location
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.

blood transfusion
solid tumor
metastatic solid tumor
growth factor
cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.

solid neoplasm
solid tumour
treatment regimen
  • 0 views
  • 16 Feb, 2024
  • 1 location
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.

  • 0 views
  • 23 Nov, 2021
  • 1 location
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of administering T cell products derived from the research participant's blood that have been genetically modified to express a …

cetuximab
suicide
solid tumor
corticosteroid therapy
biotherapy
  • 0 views
  • 16 Feb, 2024
  • 1 location
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors and Expansion in Selected Indications

This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with pembrolizumab.

programmed cell death 1 ligand 1
vegf
endometrial carcinoma
immunostimulant
urothelial carcinoma
  • 0 views
  • 05 Aug, 2020